DOCUSOL CONSTIPATION RELIEF is a brand name for Docusate. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Prevention and treatment of chronic constipation. Prevention of hard dry stools and reduction of straining at stools in the presence of conditions like haemorrhoids and anal fissures.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults: 10 mL three times a day. g. milk or orange juice. Maximum daily dose 30 mL. Treatment should be commenced with large doses which should be decreased as the condition of the patient improves.
Elderly:
There is no evidence to suggest that an adjustment of the dosage is necessary in the elderly. 5 mg/5 ml Solution. Duration of treatment The patient should be advised to consult a physician when constipation persists or worsens during treatment or when laxatives are needed for a long period of time.
Method of administration Oral use.
Frequencies are defined as follows:
Very common (≥1/10); common (≥1/100 to ≤ 1/10); uncommon (≥1/1,000 to ≤ 1/100); rare (≥1/10,000 to ≤ 1/1,00); very rare (≤ 1/10,000), not known (cannot be estimated from the available data).
Gastrointestinal disorders:
Rare: diarrhoea, nausea, abdominal cramps.
Skin and subcutaneous tissue disorders:
Not known: skin rash and pruritus. There have been spontaneous reports of burning sensation in mouth and throat following the use of docusate sodium. Patients are advised to drink plenty of water or flavoured drink after taking the solution.
Reporting of suspected adverse reactions Reporting suspected adverse reaction after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Paediatric population Docusol Constipation Relief 50 mg/5 ml Solution is not recommended for children aged 12 years and under. Docusol Constipation Relief 50 mg/5 ml Solution contains sorbitol. This medicine contains 1290 mg sorbitol in each 5 mL dose.
Sorbitol is a source of fructose so should not be given to patients who have an intolerance to some sugars or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose.
Sorbitol may cause gastrointestinal discomfort and mild laxative effect. 5 mg of propyl p-hydroxybenzoate in each 5 mL dose. May cause allergic reactions (possibly delayed). Docusol Constipation Relief 50 mg/5 ml Solution contains aspartame.
This medicine contains 15 mg aspartame in each dose (5 mL) . Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
Docusol Constipation Relief 50 mg/5 ml Solution contains sodium benzoate. This medicine contains 5 mg sodium benzoate in each dose (5 mL). Docusol Constipation Relief 50 mg/5 ml Solution contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially ‘sodium-free’.
1. • in the presence of abdominal pain, intestinal obstruction, nausea or if vomiting occurs.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Docusate in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.